Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 03/07/18 | EFFECT | Notice of Effectiveness |
|
1 | |
| 03/05/18 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
1 | |
| 03/02/18 | UPLOAD | SEC-generated letter |
|
1 | |
| 02/28/18 | SC TO-I/A | Issuer tender offer statement |
|
6 | |
| 02/28/18 | D/A | Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(a)(5) under the Act. |
|
6 | |
| 02/23/18 | S-3 | Registration statement for specified transactions by certain issuers |
|
122 | |
| 02/20/18 | SC TO-I/A | Issuer tender offer statement |
|
4 | |
| 02/20/18 | 8-K | Current report filing |
|
7 | |
| 02/20/18 | SC TO-I/A | Issuer tender offer statement |
|
4 | |
| 02/20/18 | 8-K | Current report filing |
|
3 |
